Tier 2 — strong

A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage

Giulia Lizzo, Eugenia Migliavacca, Daniela Lamers, Adrien Frézal, John Corthesy, Gerard Vinyes-Parès, Nabil Bosco, Leonidas G Karagounis, Ulrike Hövelmann, Tim Heise, Maximilian von Eynatten, Philipp Gut
Front Aging 2022 3:852569

Bibliography

PubMed
PMID 35821844
PubMed Central
PMC9261343
DOI
10.3389/fragi.2022.852569
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Multiple authors were employees of Nestlé Research or Nestlé Health Science; Nestlé Health Science holds patents/licenses and markets products involving glycine and N-acetylcysteine. Profil Institute employees were also involved, and Profil had received research funding from Nestlé Health Science.

Study snapshot

DesignRandomized controlled dose-ranging trial
ModelHuman
Sample114 healthy older adults, mean age about 65 years
InterventionGlyNAC at 2.4, 4.8 or 7.2 g/day in a 1:1 glycine:NAC ratio
Duration2 weeks
EndpointsGlutathione redox status; Oxidative damage; Dose response

What the study showed, in plain terms

Larger short-term trial testing three GlyNAC doses in healthy older adults.

Key findings

Provides controlled dose-response data for GlyNAC effects on glutathione/redox biology.

What this study can and cannot tell us

Two-week duration and combined glycine-plus-NAC intervention; does not establish long-term clinical benefit or NAC-only effects.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology